Dermata Therapeutics -CW26DRMAWPreferred / convertible
13F holders, Q1 2024 (March 31)5holders
$0.08avg. 13F price*
At the end of Q1 2024, 5 institutions reported holding Dermata Therapeutics -CW26 (DRMAW) in their 13F filings. The largest holders were Boothbay Fund Management, LLC ($5K), Warberg Asset Management LLC ($285) and Armistice Capital, LLC ($193).
- Company
- Dermata Therapeutics -CW26
- CUSIP
- 249845116
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1 |
| Exits | 0 | $0 |
Ownership 5 holders
| Boothbay Fund Management, LLC | — | No change | 12,000 | $5K |
| Warberg Asset Management LLC | — | No change | 30,000 | $285 |
| Armistice Capital, LLC | — | Reduce -93.8% | 20,312 | $193 |
| UBS Group AG | — | Reduce -55.7% | 1,485 | $15 |
| Bank of America Corp. | — | New | 100 | $1 |
"% of holder's portfolio" is DRMAW's weight in each manager's 13F, not the share of Dermata Therapeutics -CW26 the manager owns.